Table 1.
Baseline characteristics.
| Clinical feature | Training set (n = 17,934) | Internal-testing set 1 (n = 4303) | Internal-testing set 2 (n = 185) | External-testing set (n = 563) | ||||
|---|---|---|---|---|---|---|---|---|
| Disease | Patients with HT | Patients without HT | Patients with HT | Patients without HT | Patients with HT | Patients without HT | Patients with HT | Patients without HT |
| Patient number (n, %) | 6143 (34.3) | 11791 (65.7) | 1188 (27.6) | 3115 (72.4) | 52 (28.1) | 133 (71.9) | 146 (25.9) | 417 (74.1) |
| Age (median, IQR) | 46 (18) | 45 (16) | 44 (17) | 45 (17) | 40 (24) | 41 (14) | 50 (18) | 51 (16) |
| Sex (n, %) | ||||||||
| Male | 556 (9.1) | 3243 (27.5) | 140 (11.8) | 898 (28.8) | 4 (7.7) | 48 (36.1) | 10 (6.8) | 101 (24.2) |
| Female | 5587 (90.9) | 8548 (72.5) | 1048 (88.2) | 2217 (71.2) | 48 (92.3) | 85 (63.9) | 136 (93.2) | 316 (75.8) |
| Serologic marker (median, 95% CI) | ||||||||
| Tg (ug/L) | 2.81 (0.10–62.77) | 12.0 (0.57–184.89) | 3.68 (0.15–100.42) | 10.49 (0.53–99.17) | 3.26 (0.04–81.230 | 16.85 (1.77–135.20) | NA | |
| Anti-Tg (IU/mL) | 7.60 (0.92–1365.77) | 0.92 (0.92–48.6) | 15.74 (1.10–799.0) | 7.26 (0.97–903.78) | 234.0 (14.59–3521.63) | 11.0 (10.0–265.5) | NA | |
| Anti-TPO (IU/mL) | 22.34 (0.318–994.0) | 0.79 (0.25–191.67) | 15.92 (0.30–765.33) | 0.91 (0.26–126.48) | 65.5 (9.0–492.2) | 9.0 (9.0–121.50) | NA | |
| T3 (nmol/L) | 1.41 (0.97–1.95) | 1.42 (1.0–1.99) | 1.45 (0.94–2.07) | 1.49 (1.04–2.0) | 1.55 (1.19–2.32) | 1.65 (1.25––2.22) | NA | |
| T4 (nmol/L) | 99.81 (73.32–141.39) | 101.0 (72.26–137.98) | 95.89 (62.99–139.35) | 97.55 (64.51–134.82) | 89.8 (66.40–145.95) | 91.2 (64.7–129.0 | NA | |
| TSH (mIU/L) | 2.29 (0.11–8.61) | 1.98 (0.36–6.0) | 2.33 (0.12–10.80) | 2.09 (0.38–6.56) | 2.29 (0.24–10.54) | 1.91 (0.59–4.21) | NA | |